Influencing and prognostic factors of end-stage hypertrophic cardiomyopathy

被引:0
作者
Zhang, Yisen [1 ]
Xie, Wenhui [2 ]
Dai, Yaqing [2 ]
Wu, Zefeng [2 ]
Lin, Yuping [2 ]
Yang, Ming [2 ]
Hong, Huashan [2 ]
机构
[1] Fujian Med Univ, Union Hosp, Fujian Inst Geriatr, Fujian Heart Dis Ctr,Dept Cardiac Surg,Fujian Key, Fuzhou, Peoples R China
[2] Fujian Med Univ, Union Hosp, Fujian Inst Geriatr, Fujian Clin Res Ctr Senile Vasc Aging & Brain Agin, Xinquan Rd 29, Fuzhou 350001, Fujian, Peoples R China
来源
ESC HEART FAILURE | 2024年 / 11卷 / 06期
关键词
End-stage phase; Death; Heart transplantation; Hypertrophic cardiomyopathy; HEART-FAILURE; ASSOCIATION; PREVALENCE; DURATION; DISEASE;
D O I
10.1002/ehf2.15010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims End-stage hypertrophic cardiomyopathy (ES-HCM) is a disease with severe complications and a poor prognosis. This study aimed to explore the influencing and prognostic factors of ES-HCM. Methods and results A total of 1282 patients with HCM who were hospitalized for the first time at Fujian Medical University Union Hospital between 1 January 2013 and 30 September 2021 were recorded. The patients with HCM and left ventricular ejection fraction (LVEF) < 50% were defined as having ES-HCM, and a control group (LVEF >= 50%) was generated from the collected medical records of HCM. The patients were matched in a ratio of 4:1 based on age and sex. Logistic regression analysis was used to determine the influencing factors of ES-HCM. Kaplan-Meier survival analysis was performed to analyse the clinical outcomes of ES-HCM patients. A total of 250 inpatients with HCM were enrolled in the study; 50 patients had ES-HCM, and 200 had HCM with LVEF >= 50%. The mean age of the patients at enrolment was 62.5 +/- 10.3 years, and 215 patients (215/250, 86.0%) were male. The median follow-up time of the patients was 2.8 (1.4-5.4) years. The incidence of all-cause death and cardiovascular death in patients with ES-HCM was higher than those in patients with HCM and LVEF >= 50% (22/50 [44.0%] vs. 13/200 [6.5%]; 12/50 [24.0%] vs. 4/200 [2.0%], all P < 0.001). Multivariate logistic regression analysis showed that the influencing factors associated with ES-HCM included age at first symptom onset (odds ratio [OR] = 0.95, 95% CI [0.90, 1.00], P = 0.042), New York Heart Association (NYHA) class (OR = 7.73, 95% CI [2.93, 20.41], P < 0.001), heart rate (OR = 1.07, 95% CI [1.02, 1.12], P = 0.003), QRS duration (OR = 1.03, 95% CI [1.00, 1.05], P = 0.020), left ventricular end-diastolic diameter (LVEDD) (OR = 1.15, 95% CI [1.04, 1.28], P = 0.006), left atrial anteroposterior diameter (LAD) (OR = 1.13, 95% CI [1.03, 1.24], P = 0.012), and maximum left ventricular wall thickness (MLVWT) (OR = 0.80, 95% CI [0.68, 0.93], P = 0.005). Among the 50 patients with ES-HCM, NYHA class (P < 0.001) and heart rate (P = 0.017) were each associated with a higher likelihood and earlier occurrence of heart transplantation or all-cause mortality in univariate analyses. Conclusions The influencing factors for ES-HCM included the age at first symptom onset, NYHA class, heart rate, QRS duration, LVEDD, LAD, and MLVWT. Both NYHA class and heart rate were related to the prognosis of ES-HCM.
引用
收藏
页码:4028 / 4037
页数:10
相关论文
共 38 条
  • [1] Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?
    Achim, Alexandru
    Serban, Adela Mihaela
    Mot, Stefan Dan Cezar
    Leibundgut, Gregor
    Marc, Madalin
    Sigwart, Ulrich
    [J]. ESC HEART FAILURE, 2023, 10 (03): : 1570 - 1579
  • [2] Commentary on the enigma of small vessel disease in hypertrophic cardiomyopathy: is invasive assessment of microvascular resistance a novel independent predictor of prognosis?
    Achim, Alexandru
    Savaria, Badal U.
    Buja, L. Maximilian
    [J]. CARDIOVASCULAR PATHOLOGY, 2022, 60
  • [3] Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function
    Ahmed, A
    Aronow, WS
    Fleg, JL
    [J]. AMERICAN HEART JOURNAL, 2006, 151 (02) : 444 - 450
  • [4] Resting heart rate and the risk of cardiovascular disease, total cancer, and all-cause mortality - A systematic review and dose-response meta-analysis of prospective studies
    Aune, D.
    Sen, A.
    o'Hartaigh, B.
    Janszky, I.
    Romundstad, P. R.
    Tonstad, S.
    Vatten, L. J.
    [J]. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2017, 27 (06) : 504 - 517
  • [5] Hypertrophic Cardiomyopathy from A to Z: Genetics, Pathophysiology, Imaging, and Management
    Baxi, Ameya Jagdish
    Restrepo, Carlos S.
    Vargas, Daniel
    Marmol-Velez, Alejandro
    Ocazionez, Daniel
    Murillo, Horacio
    [J]. RADIOGRAPHICS, 2016, 36 (02) : 335 - 354
  • [6] Sex-specific risk factors of carotid atherosclerosis progression in a high-risk population of cardiovascular disease
    Cheng, Qi
    Zhou, Dan
    Wang, Jiabin
    Nie, Zhiqiang
    Feng, Xiaoxuan
    Huang, Yuqing
    Liang, Qiaomin
    Feng, Yingqing
    [J]. CLINICAL CARDIOLOGY, 2023, 46 (01) : 22 - 31
  • [7] Heart rate: A global target for cardiovascular disease and therapy along the cardiovascular disease continuum
    Custodis, Florian
    Reil, Jan-Christian
    Laufs, Ulrich
    Boehm, Michael
    [J]. JOURNAL OF CARDIOLOGY, 2013, 62 (3-4) : 183 - 187
  • [8] Epidemiology of heart failure
    Groenewegen, Amy
    Rutten, Frans H.
    Mosterd, Arend
    Hoes, Arno W.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (08) : 1342 - 1356
  • [9] Hamada Tomoyuki, 2010, Clin Cardiol, V33, pE24, DOI 10.1002/clc.20533
  • [10] Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy
    Harris, Kevin M.
    Spirito, Paolo
    Maron, Martin S.
    Zenovich, Andrey G.
    Formisano, Francesco
    Lesser, John R.
    Mackey-Bojack, Shannon
    Manning, Warren J.
    Udelson, James E.
    Maron, Barry J.
    [J]. CIRCULATION, 2006, 114 (03) : 216 - 225